COGNITIVE DISORDERS IN PATIENTS WITH PARKINSON'S DISEASE ON THE BACKGROUND OF AUTOIMMUNE PATHOLOGY
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by the predominantly dopaminergic neuronal black matter degeneration. The multicentre study of PRIAMO (PaRkinson & non Motor symptom) showed that in 98.6 % of cases, non-motor symptoms (NMS) were observed in patients with PD. Cognitive impairment is one of the most common NMS PD. According to these studies, cognitive dysfunction develops in most patients at an early stage of the disease, with mild to moderate cognitive impairment. In the later stages of the disease, dementia occurs in 80 % of patients with PD.
Aim of the research. To study the peculiarities of cognitive impairment in patients with PD and autoimmune thyroiditis (AIT), their association with motor and non-motor disorders, and to assess the impact on the quality of life of patients.
Materials and methods of the research. 109 patients with PD aged 47 to 75 years were examined. The main group consisted of patients with IA and IB subgroups, control – IIA and IIB subgroups. General clinical and neurological examinations, evaluation of motor functions by the Unified Parkinson's disease Rating Scale (UPDRS), neuropsychological testing (MMSE, MoCA, FAB, BDI), Hamilton's Alert Scale (HARS), scale used for assessing autonomic disorders in patients with PD and Parkinson’s disease questionnaire (PDQ-39), statistical analysis using the "Statistica 6.0" program.
Results. Neuropsychological testing showed that MMSE, MoCA, and FAB obtained from patients with PD and AIT are lower compared to patients with PD. Analyzing the indicators of MMSE, FAB, and MoCA scales in dynamics, a statistically significant difference was found in subgroups of IB and IIB; in subgroups of IA and IIA – was not observed. During the analysis of the results of the neuropsychological testing, no association was found at the statistically significant level in the subgroups of IA and IB between the duration of the disease and MMSE, MoCA, and FAB scales. In the IA subgroup, in the initial review, feedback was observed on a statistically significant level of average strength between the level of anxiety and the indicator of the MMSE scale, an indicator of the MoCA scale. In the IA subgroup, there was no relationship at the statistically significant level between the indicators of neuropsychological testing (MMSE, MoCA, FAB) and motor and non-motor manifestations (depression, vegetative disorders). There was a connection at a statistically significant level between the indicators of neuropsychological testing (MMSE, MoCA, FAB) and motor and non-motor manifestations of PD in patients who received anti-parkinsonian therapy for a long period of time. The negative influence of the level of cognitive impairments on the quality of life of patients with PD and AIT was revealed, indicating the high medical and social significance of these violations.
Conclusions. Neuropsychological testing showed that MMSE, MoCA, FAB scores in patients with PD and AIT (IB subgroup) were lower compared to patients with PD (IIB subgroup). There was a connection at a statistically significant level between the indicators of neuropsychological testing (MMSE, MoCA, FAB) and motor and non-motor manifestations of PD in patients who received anti-parkinsonian therapy for a long period of time. The negative influence of the level of cognitive impairments on the quality of life of patients with PD and AIT was revealed, indicating the high medical and social significance of these violations.
Downloads
References
Hanganu, A., Houde, J.-C., Fonov, V. S. Degroot, C., Mejia-Constain, B., Lafontaine, A.-L. et. al. (2018). White Matter Degeneration Profile in the Cognitive Cortico-Subcortical Tracts in Parkinson’s Disease. Movement Disorders, 33 (7), 1139–1150. doi: http://doi.org/10.1002/mds.27364
Berg, D., Postuma, R. B., Bloem, B., Chan, P., Dubois, B., Gasser, T. et al. (2014). Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Movement Disorders, 29 (4), 454–462. doi: http://doi.org/10.1002/mds.25844
Goldman, J. G., Postuma, R. (2014). Premotor and nonmotor features of Parkinsonʼs disease. Current Opinion in Neurology, 27 (4), 434–441. doi: http://doi.org/10.1097/wco.0000000000000112
Schrag, A., Horsfall, L., Walters, K., Noyce, A., Petersen, I. (2015). Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. The Lancet Neurology, 14 (1), 57–64. doi: http://doi.org/10.1016/s1474-4422(14)70287-x
Barone, P., Antonini, A., Colosimo, C., Marconi, R., Morgante, L., Avarello, T. P. et. al. (2009). The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Movement Disorders, 24 (11), 1641–1649. doi: http://doi.org/10.1002/mds.22643
Delgado-Alvarado, M., Gago, B., Navalpotro-Gomez, I., Jiménez-Urbieta, H., Rodriguez-Oroz, M. C. (2015). Biomarkers for dementia and mild cognitive impairment in Parkinson’s disease. Movement Disorders, 31 (6), 861–881. doi: http://doi.org/10.1002/mds.26662
Levin, O. S., Fedorova, N. V. (2014). Parkinson’s disease. Moscow: MEDpress-inform, 384.
Aarsland, D. (2016). Cognitive impairment in Parkinson’s disease and dementia with Lewy bodies. Parkinsonism & Related Disorders, 22 (1), 144–148. doi: http://doi.org/10.1016/j.parkreldis.2015.09.034
Arnaldi, D., De Carli, F., Famà, F., Brugnolo, A., Girtler, N., Picco, A. et al. (2017). Prediction of Cognitive Worsening in De Novo Parkinson’s Disease Clinical Use of Biomarkers. Movement Disorders, 32 (12), 1738–1747. doi: http://doi.org/10.1002/mds.27190
Anang, J. B. M., Gagnon, J.-F., Bertrand, J.-A., Romenets, S. R., Latreille, V., Panisset, M. et. al. (2014). Predictors of dementia in Parkinson disease: A prospective cohort study. Neurology, 83 (14), 1253–1260. doi: http://doi.org/10.1212/wnl.0000000000000842
Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A. (2003). Prevalence and Characteristics of Dementia in Parkinson Disease. Archives of Neurology, 60 (3), 387–392. doi: http://doi.org/10.1001/archneur.60.3.387
Mak, E., Su, L., Williams, G. B., Firbank, M. J., Lawson, R. A., Yarnall, A. J. et. al. (2015). Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain, 138 (10), 2974–2986. doi: http://doi.org/10.1093/brain/awv211
Agosta, F., Canu, E., Stefanova, E., Sarro, L., Tomic, A., Spica, V. et. al. (2014). Mild cognitive impairment in Parkinson’s disease is associated with a distributed pattern of brain white matter damage. Human Brain Mapping, 35 (5), 1921–1929. doi: http://doi.org/10.1002/hbm.22302
Zheng, Z., Shemmassian, S., Shemmassian, S., Kim, W., Bookheimer, S. Y., Pouratian, N. (2014). DTI correlates of distinct cognitive impairmentsin Parkinson’s disease. Human Brain Mapping, 35 (4), 1325–1333. doi: http://doi.org/10.1002/hbm.22256
Ray Chaudhuri, K., Poewe, W., Brooks, D. (2018). Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features. Movement Disorders, 33 (6), 909–919. doi: http://doi.org/10.1002/mds.27386
Baggio, H. C., Segura, B., Sala-Llonch, R., Marti, M.-J., Valldeoriola, F., Compta, Y. et. al. (2015). Cognitive impairment and resting-state network connectivity in Parkinson’s disease. Human Brain Mapping, 36 (1), 199–212. doi: http://doi.org/10.1002/hbm.22622
Fengler, S., Liepelt-Scarfone, I., Brockmann, K., Schäffer, E., Berg, D., Kalbe, E. (2017). Cognitive Changes in Prodromal Parkinson’s Disease: A Review. Movement Disorders, 32 (12), 1655–1666. doi: http://doi.org/10.1002/mds.27135
Nodel', M. R., Danilova, N. N., Glozman, Zh. M., Yakhno, N. N. (2016). The correlation of cognitive, emotional and affective disorders in patients with parkinson’s disease. The Neurological Journal, 21 (6), 338–343. doi: http://doi.org/10.18821/1560-9545-2016-21-6-338-343
Hely, M. A., Morris, J. G., Reid, W. G., Trafficante, R. (2005). Sydney multicenter study of Parkinson’s Disease: non-L-dopa responsive problems dominate at 15 years. Movement Disorders, 20 (2), 190–199. doi: http://doi.org/10.1002/mds.20324
Valkovic, P., Harsany, J., Hanakova, M., Martinkova, J., Benetin, J. (2014). Nonmotor Symptoms in Early- and Advanced-Stage Parkinson’s Disease Patients on Dopaminergic Therapy: How Do They Correlate with Quality of Life? ISRN Neurology, 2014, 1–4. doi: http://doi.org/10.1155/2014/587302
Duncan, G. W., Khoo, T. K., Yarnall, A. J., O'Brien, J. T., Coleman, S. Y., Brooks, D. J. et. al. (2014). Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Movement Disorders, 29 (2), 195–202. doi: http://doi.org/10.1002/mds.25664
Copyright (c) 2018 Tetiana Cheboraka, Tatyana Slobodin, Yurii Holovchenko
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
